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ABSTRACT
The secretion of proteins that lack a signal sequence to the extracellular milieu is regulated by their
transition through the unconventional secretory pathway. IDE (insulin-degrading enzyme) is one of the
major proteases of amyloid beta peptide (Ab), a presumed causative molecule in Alzheimer disease (AD)
pathogenesis. IDE acts in the extracellular space despite having no signal sequence, but the underlying
mechanism of IDE secretion extracellularly is still unknown. In this study, we found that IDE levels were
reduced in the cerebrospinal ﬂuid (CSF) of patients with AD and in pathology-bearing AD-model mice.
Since astrocytes are the main cell types for IDE secretion, astrocytes were treated with Ab. Ab increased
the IDE levels in a time- and concentration-dependent manner. Moreover, IDE secretion was associated
with an autophagy-based unconventional secretory pathway, and depended on the activity of RAB8A and
GORASP (Golgi reassembly stacking protein). Finally, mice with global haploinsufﬁciency of an essential
autophagy gene, showed decreased IDE levels in the CSF in response to an intracerebroventricular (i.c.v.)
injection of Ab. These results indicate that IDE is secreted from astrocytes through an autophagy-based
unconventional secretory pathway in AD conditions, and that the regulation of autophagy is a potential
therapeutic target in addressing Ab pathology.
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Introduction
Alzheimer disease (AD) is characterized by senile plaques, neu-
roﬁbrillary tangles, and neuronal cell death.1 Abnormal aggre-
gates of the amyloid-beta peptide (Ab) are deposited in the
extracellular senile plaques and are associated with neurode-
generation in AD.2 In AD brains, intracellular and extracellular
Ab accumulation occurs because of the imbalance between the
production of Ab and its removal (clearance) from the brain.
IDE (insulin-degrading enzyme) is a major endogenous Ab
degrading enzyme that mediates Ab clearance, and its levels
and enzymatic activity are negatively correlated with the size of
the amyloid plaques and AD pathology.3 In AD brains, IDE is
mainly detected in astrocytes,4 and located in the cytosol and
intracellular compartments such as mitochondria and peroxi-
somes.5 However, it is also known to play a role in the extracel-
lular milieu via the secretory pathway.6 IDE has no signal
peptide sequence for secretion through the conventional secre-
tory pathway, and despite many studies demonstrating that
IDE is secreted and/or associated with the cell surface, little is
known about the underlying secretory mechanism.
Macroautophagy (hereafter referred to as autophagy) is a
fundamental biological process in eukaryotes,7 and has an
impact on essential biological processes in human health
including aging, cancer, neurodegenerative disease, immunity,
and metabolic disorders.8,9 Autophagy is currently best known
as a degradative pathway that delivers cytoplasmic material and
organelles to the lysosomes for degradation.10 All autophagy-
related processes include the formation of double-membrane
structures called the autophagosomes, and are induced by the
inhibition of MTOR (mechanistic target of rapamycin [serine/
threonine kinase]) signaling pathway. Autophagosomes and
their contents undergo clearance upon fusion with endosomes
(amphisomes) or lysosomes (autolysosomes) for degradation
and recycling (autophagic ﬂux).7,10 However, recent studies
show that autophagy also has a role in nonautophagic pro-
cesses, especially in the secretory pathway.11 In eukaryotic cells,
the autophagy-based secretory pathway (autosecretion12) regu-
lates the unconventional secretion of several cytosolic proteins
such as IL1B (interleukin 1, beta), IL18, HMGB1 (high mobility
group box 1), and VWF (von Willebrand factor), as well as
ATP.13-15 There are 3 principal features deﬁning autophagy-
based secretion: 1) proteins lacking a signal sequence, 2) contri-
bution of autophagy-related (ATG) genes, and 3) association
with GORASP (Golgi reassembly and stacking protein).16
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In the brains of patients with AD and animal models, patho-
logical autophagic vacuoles (AVs) are accumulated through
increased induction via the AMPK-MTOR pathway and dys-
function in the autophagy-lysosomal degradation.17-19 Main-
taining autophagic ﬂux is important for cell survival, and
dysregulated autophagy is expected to accelerate AD progres-
sion; however, the mechanism is not yet fully understood. In
this study, we found that Ab increased IDE secretion from
astrocytes in a time- and concentration-dependent manner,
and Ab-induced IDE secretion was associated with autophagy.
In addition, in vitro and in vivo data suggests that autophagic
ﬂux is important in IDE secretion. GORASP and RAB8A also
had a role in IDE secretion. To determine the IDE secretion lev-
els in vivo, the cerebrospinal ﬂuid (CSF) was analyzed because
the CSF has more physical contact with the brain than any
other ﬂuid in the body, as it is not separated from the brain by
the tightly regulated blood brain barrier (BBB). We found that
the mice with global haploinsufﬁciency of an ATG7 (Atg7C/¡
mice) showed decreased IDE activities and expression levels in
CSF in response to an intracerebroventricular (i.c.v.) injection
of Ab, indicating that this Ab-induced IDE secretion is medi-
ated by autophagy. Investigating the role of autophagy on IDE
secretion in the AD brain revealed that 1.5-mo-old Tg6799
mice, an AD mouse model,20 showed increased IDE secretion
in the CSF compared to the littermate control mice. The CSF of
7-mo-old Tg6799, however, showed reduced IDE level, and
dysfunction in the lysosome. Finally, CSF from patients with
AD showed decreased IDE activity and level, and this reduction
was correlated with cognitive impairment in AD patients using
clinical dementia rating (CDR) and mini-mental state examina-
tion (MMSE) scores. Overall, these results indicate that IDE is
secreted from astrocytes through autophagy-based secretory
pathway in AD, and regulation of autophagy is a potential ther-
apeutic target in Ab pathology.
Results
Ab induces extracellular secretion of functional IDE from
astrocytes
Previous studies have reported astrocytes as a main source for
IDE in AD pathology;4 therefore, we determined whether
Ab regulates IDE levels in the extracellular space of astrocytes.
Exogenous Ab1-42, but not Ab42-1 (reverse form of Ab1-42;
revAb), increased IDE secretion from the mouse primary astro-
cytes and human astrocytoma cells, U373MG, in a time- and
dose-dependent manner (Fig. 1A to C for primary astrocytes;
Fig. S1A and B for U373MG cells). To determine whether the
IDE secretion is regulated by Ab, Ide siRNA was transfected
into astrocytes. Ab increased IDE secretion in the scrambled
siRNA-transfected cells, but not the Ide siRNA-transfected cells
(Fig. S1C and D). To examine whether the IDE secreted by
Ab treatment has a function as insulysin (an insulin-degrading
function), an IDE enzymatic activity assay was adopted.
Increased ﬂuorescence intensity generated by the cleavage of
ﬂuorometric IDE substrates in the Ab-treated, astrocyte-condi-
tioned media (Ab-ACM) was detected (Fig. 1D). When bacitra-
cin A, an IDE inhibitor, was added to the Ab-ACM, the
ﬂuorescence intensity was decreased, while thiorphan, a MME
(membrane metallo-endopeptidase) inhibitor, did not alter the
increased ﬂuorescence intensity by Ab (Fig. 1D), indicating
that Ab-ACM contains functional IDE that degrades insulin.
In an alternative approach, Ab degradation assay was per-
formed. When the Ab-ACM was incubated with recombinant
Ab peptide, the level of the remaining Ab peptide was reduced
(Fig. 1E and F). Furthermore, the reduced Ab levels after incu-
bation with the Ab-ACM were restored when either bacitracin
A or insulin (competing partner of Ab to IDE) was added
(Fig. 1F). These data demonstrate that Ab-induced IDE,
secreted from astrocytes, functions as a protease.
Ab-induced IDE secretion is associated with an
autophagy-based unconventional secretory pathway
To examine the mechanism of Ab-induced IDE secretion, tran-
script levels of IDE after Ab treatment were measured by RT-
PCR and qPCR (quantitative real-time PCR). Ab did not alter
Ide mRNA levels in astrocytes (Figs. 2A and B). Since IDE has
no signal sequence for secretion, we further investigated the
secretory mechanism of IDE. To examine the IDE secretion via
an unconventional secretory pathway, BFA (brefeldin A), a
blocker of conventional secretion, was added along with Ab.
BFA failed to inhibit Ab-induced IDE secretion, and even
increased IDE secretion (Fig. S1E and F). Because MMP9
(matrix metallopeptidase 9), another Ab-degrading enzyme,
has a signal sequence, BFA inhibited MMP9 secretion in the
Ab treatment (Fig. S1G). Our results also conﬁrmed that the
secretion of HMGB1, a previously known protein secreted
through unconventional secretory pathway,13 increased after
BFA treatment, similarly to IDE (Fig. S1H). Because BFA
induced the endoplasmic reticulum (ER) stress (indicated by
increased DDIT3 levels; Fig. S1E and I) and increased IDE
secretion (Fig. S1E and F), we investigated the role of ER stress
on IDE secretion. We found that treatment with TUDCA, a
chemical chaperone which can reduce ER stress,21 inhibited
Ab-induced IDE secretion from primary astrocytes (Fig. S1J).
Recent reports have shown that autophagy plays a role in
unconventional protein secretion in mammalian cells.11,13,14,22
To examine whether Ab-induced IDE secretion is associated
with autophagy, we utilized several autophagic modulators. We
found that Ab-induced autophagy is activated in astrocytes
(Fig. 2C and D; Fig. S2A and B), and that Ab modulated the
AMP-activated protein kinase (PRKA)-MTOR signal pathway,
which in turn can regulate autophagy induction (Fig. S2C).17
When 3-methyladenine (3MA), an autophagy inhibitor, was
added along with Ab, Ab-induced IDE secretion was signiﬁ-
cantly inhibited by 3MA (Fig. 2C and D; Fig. S2A), but not
MMP9 (Fig. S1G). These data were conﬁrmed by inhibiting
autophagy with Atg5 siRNA (Fig. 2E). To activate autophagy,
rapamycin, a functional autophagy inducer that inhibits
MTOR, was applied to astrocytes, resulting in increased IDE
secretion from astrocytes (Fig. 2F). To investigate whether IDE
exists in the autophagosomes, IDE and LC3 were stained with
their speciﬁc antibodies and then visualized using confocal
microscopy and super resolution microscopy. Immunocyto-
chemistry data showed that IDE was located in the autophago-
somes (Fig. 2G and H). Taken together, these data imply that
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Ab-induced IDE secretion is tightly regulated by the autophagy
pathway.
IDE is degraded through the proteasome pathway
Since the treatment with proteasome inhibitor, MG132,
increased the IDE levels (Fig. 2F), IDE might be a substrate for
the proteasome. To examine this possibility, astrocytes were
cotreated with MG132 and Ab, resulting in increased IDE lev-
els both intracellularly and extracellularly (Fig. S3A and B).
Moreover, treatment with MG132 alone also increased IDE lev-
els compared to vehicle treatment (Fig. S3A and B), indicating
that basal IDE levels were regulated by the proteasome
pathway.
Figure 1. Ab induces extracellular secretion of functional IDE from primary astrocytes. (A, B) Increased IDE levels secreted from the primary astrocytes with Ab treatment,
in a concentration-(A) and time-(B) dependent manner. Treatments were 0.5, 1 or 2 mM of Ab for 24 h (A), and 1 mM of Ab for 1, 3, 12 or 24 h (B). Blots are representative
of at least 3 independent experiments. (C) Measurement of IDE levels in the media from primary astrocytes by ELISA. (D) IDE enzymatic activity in media containing 1 mM
Ab and/or several inhibitors (Thiorphan [10 mM], Bacitracin A [10 mM]) for 24 h. Baci. A, Bacitracin A. (E) Cell-free Ab degradation assay. rIDE, recombinant IDE protein
(0.3 ng/mL). The arrowhead indicates remaining Ab levels. Data were obtained from at least 3 replicates for each group (N D 3 experiments). (F) Ab degradation assay
with several drugs. Ins, insulin (0.5 mM); Baci. A, bacitracin A (10 mM). Data were obtained from at least 3 replicates for each group (N D 3 experiments). Values are
mean § SEM , P < 0.05; , P < 0.01; and , P < 0.001 vs. vehicle-treated cells; #, P < 0.05 vs. cells treated with Ab.
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Figure 2. Ab-induced IDE secretion from primary astrocytes is associated with the autophagy-mediated unconventional secretion pathway. (A) RT-PCR analysis of Ide
mRNA levels under Ab treatment conditions. (B) Quantiﬁcation of Ide mRNA levels by qPCR. (C) Increased LC3-II levels in astrocytes by Ab treatment demonstrate the role
of autophagy in Ab-induced IDE secretion; 3-MA (1 mM) was administered to vehicle- or Ab-treated cells. (D) Quantitative analysis of Fig. 2C (N D 4 experiments). (E)
Western blot analysis of IDE levels in the media from Atg5 knockdown primary astrocytes. Representative images are shown, and data are represented as mean § SEM
from 4 independent experiments (ND 4 experiments). (F) Western blot analysis of secreted IDE levels from astrocytes after the treatment with inhibitors and/or activators
in the presence of Ab (1 mM for 24 h). Rap, rapamycin (2 mM for 6 h); MG, MG132 (5 mM for 6 h). Representative images are shown, and data are represented as mean §
SEM from 3 independent experiments (N D 3 experiments). (G) 3D-SIM reconstruction images of IDE expression in the autophagosomes. The 3D-SIM image was taken in
a z-direction with a thickness of 0.150 mm, reconstructed into a 3D volume image. Scale bar represents 10 mm in the image with confocal microscopy. Low panels (a1,
a2, and a3) show enlarged images using 3D-SIM. The b1 and b2 panels show lines of ﬂuorescence tracing from images in a3. (H) The Pearson colocalization coefﬁcient for
IDE and LC3. The Pearson coefﬁcient was derived from 3 independent experiments with 3 ﬁelds per experiment, for a total of 9 ﬁelds contributing to the cumulative
result. , P < 0.05; and , P < 0.01 vs. vehicle-treated cells; #, P < 0.05; and ##, P < 0.01 vs. cells treated with Ab. n.s. indicates not signiﬁcant.
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Autophagic ﬂux is important for Ab-induced IDE secretion
To determine the effect of the autophagy-lysosomal pathway on
Ab-induced IDE secretion, we investigated the change in lyso-
somal function following treatment with Ab. When levels of
ATP6V0A1 (ATPase, HC transporting, lysosomal V0 subunit
a1) and the mature form of CTSD (cathepsin D) were analyzed
by western blotting (WB), we found that treatment with 1mM
Ab resulted in increased astrocytic expression of the mature
form of CTSD (Fig. 3A). Dupont et al. (2011)13 reported that
the secretion of IL1B, a substrate for autophagy-based secre-
tion, was inhibited under conditions of lysosomal dysfunction,
as induced by treatment with baﬁlomycin A1 (Baf; an inhibitor
of vacuolar ATPase, which prevents lysosomal acidiﬁcation
and autophagosomal cargo degradation). To further examine
the Ab-induced IDE secretory pathway, Baf was used to block
fusion between the autophagosome and the lysosome. If IDE is
a substrate for autophagy-lysosomal degradation, Baf may
increase total IDE levels intracellularly and extracellularly.
When a monomeric red ﬂuorescent protein-green ﬂuorescent
protein (mRFP-GFP) tandem ﬂuorescence-tagged LC3 (Tf-
LC3) construct was transfected to U373MG cells, Baf treatment
increased the yellow signal (produced by the mRFP-GFP fusion
form), indicating that the fusion of autophagosomes with lyso-
somes is blocked (Fig. 3B). Baf treatment decreased IDE secre-
tion from astrocytes (Fig. 3C), suggesting that autophagic ﬂux
is important for IDE secretion and IDE is not a substrate for
the autophagy-lysosomal pathway (Fig. 3C). In addition, by
live-cell imaging, we observed that IDE colocalized with the
autophagosome (MDC-positive) and lysosome (LysoTracker
Red-positive), and that Ab accelerated the colocalization of
IDE with the lysosome (Fig. S4A and B). To determine the
involvement of lysosome function in Ab-induced IDE secre-
tion, restoration of the lysosome function was challenged by
PP242, a well-known ATP-competitive MTOR inhibitor that
activates the lysosomal function.23 When PP242 was added
together with Ab, the signal intensity of BODIPY FL pepstatin
A, a ﬂuorescent probe for CTSD,24 increased (Fig. 3D and E),
suggesting that PP242-induced lysosome activation in astro-
cytes. PP242 restored IDE secretion, which was decreased by
Baf treatment (Fig. 3F and G). Considered together, these data
indicate that autophagic ﬂux is important for Ab-induced IDE
secretion.
The SlyX domain of IDE regulates IDE secretion by
protecting degradation through the lysosome
Then, how can IDE protein escape from the lysosome without
degradation? Previous studies demonstrate that the SlyX motif,
a novel amino acid motif (853EKPPHY858) close to the C termi-
nus of IDE, determines IDE secretion –and yet, the mechanism
by which it does so remains elusive.25 To examine whether the
SlyX domain of IDE has a role in protection from lysosomal
degradation, protein stability was measured with IDE wild type
(IDE WT) or SlyX domain-deletion mutant (IDE DS)-trans-
fected U373MG cells. When cycloheximide (CHX) was added
into U373MG cells, IDE DS degraded faster than IDE WT
(Fig. 4A). Moreover, we found that following Ab treatment,
IDE DS levels in the cells decreased—this can be reversed by
inhibition of the lysosomes (Fig. 4B and C). Secretion of IDE
DS decreased more than that of IDE WT under both basal and
Ab treatment conditions (Fig. 4D and E). These data indicate
that the SlyX domain of IDE regulates Ab-induced IDE secre-
tion by preventing its lysosomal degradation.
Ab-induced IDE secretion is mediated by RAB8A activity
Several factors regulate the secretion of IDE. A previous study
reports multiple roles of small GTPase RAB proteins in the
secretory pathway.26 In particular, RAB8A is known as one of
the main regulators of membrane fusion and exocytosis.13,27 To
determine whether RAB8A regulates IDE secretion from astro-
cytes, we treated the Rab8a and Rab5 (as control) siRNA-trans-
fected cells with Ab (Fig. 5A and S5A). In Rab8a, but not Rab5,
knockdown cells, IDE secretion was reduced signiﬁcantly under
Ab treatment conditions (Fig. 5A), suggesting that RAB8A was
required for the enhanced IDE secretion caused by Ab treat-
ment. To investigate the association of RAB8A protein with
Ab-induced IDE secretion, the protein levels and the cellular
localization of RAB8A were examined. When astrocytes were
treated with Ab, the RAB8A protein level was unchanged
(Fig. S5B). However, RAB8A protein clustered in the cytoplasm
following Ab treatment (Fig. S5C). In this condition, RAB8A
surprisingly colocalized with LC3-positive organelles, the auto-
phagosomes (Fig. S5D). Furthermore, RAB8A dominant nega-
tive (DN) construct (RAB8AS22N) inhibited Ab-induced IDE
secretion (Fig. 5B), indicating that RAB8A plays an important
role in Ab-induced IDE secretion. Then, how does Ab affect
RAB8A to modulate IDE secretion? Hooff et al. (2010) report
that RAB prenylation, which is the addition of GGPP (geranyl-
geranylpyrophosphate) to a RAB protein, is necessary to regu-
late the activity of RAB proteins because RAB protein should
be inserted into membranes to activate various biochemical
pathways.28 Since Ab leads to the inhibition of prenylation in
the neurons according to a previous study,29 we examined
whether Ab regulates prenylation of RAB8A in astrocytes.
When Ab was applied to astrocytes, unprenylated RAB8A was
increased, and conversely, prenylated RAB8A was decreased
(Fig. S5E). This effect was restored by GGPP treatment
(Fig. S5E). In addition, Ab-induced IDE secretion was reduced
by cotreatment with GGPP (Fig. 5C), suggesting that the
increased unprenylation of RAB8A induced IDE secretion. To
conﬁrm these results, we established RAB8A prenylation-deﬁ-
cient mutant cells (RAB8AC204A) (Fig. S5F and G). When the
prenylation-deﬁcient mutant of RAB8A was expressed, IDE
secretion increased over that in RAB8A wild type (WT)-
expressing cells (Fig. 5D). These data indicate that IDE secre-
tion is mediated by RAB8A activity, and that Ab increases IDE
secretion from astrocytes by the inhibition of RAB8A
prenylation.
GORASP regulates Ab-induced IDE secretion by regulating
autophagy
Since previous studies have reported that GORASP proteins
control unconventional secretion of Acb1 in yeast and IL1B in
macrophages,13,30,31 we examined whether GORASP (GOR-
ASP1 and GORASP2 in mammals) regulate Ab-induced IDE
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Figure 3. Autophagic ﬂux is important for Ab-induced IDE secretion. (A) Change in lysosomal proteins in primary astrocytes following treatment with Ab (1 mM for 24 h).
FL, full-length; m, mature form; CTSD, cathepsin D. CANX is a loading control for the membrane fraction. Representative images are shown, and data are represented as
mean § SEM from 3 independent experiments (N D 3 experiments). (B) Determination of autophagic ﬂux using the Tf-LC3 construct. U373MG cells were preincubated
with or without 10 nM Baf for 2 h, then exposed to 1 mM Ab for 24 h. Cells were treated with rapamycin (Rap) for 6 h. The mRFP-positive dots indicate only mRFP-LC3 sig-
nals (autolysosome), and the yellow signal indicates colocalization of GFP and mRFP signals (defects in autophagic maturation). Scale bar represents 10 mm. Values repre-
sent the number of positive dots for red signals and yellow signals, and are mean § SEM of 50 different cells in each independent experiment (N D 3). (C) Western blot
analysis of IDE secretion after treatment with the lysosome inhibitor, Baf. L.E. indicates long exposure. (D) Lysosomal activity was determined with LysoTracker Red probe
or BODIPY-FL-Pepstatin probe (for detection of active CTSD). The white arrows represent active CTSD signals, and Ab-induced lysosomal clustering. Scale bar represents
10 mm. (E) Quantitative analysis of Fig. 3D (N D 3 experiments). (F) Secreted IDE levels under the lysosome-modulating conditions (Baf, PP242 or Baf C PP242). Baf
(10 nM for 2 h), PP242 (5 mM for 2 h) (G) Quantitative analysis of Fig. 3F (N D 3 experiments). B, Baf; P, PP242. , P < 0.05; , P < 0.01; and , P < 0.001 vs. vehicle-
treated cells; #, P < 0.05; ##, P < 0.01; and ###, P < 0.001 vs. cells treated with Ab; x, P < 0.05; and xx, P < 0.01 vs. cells treated with Ab C Baf; &&, P < 0.01 vs. cells
treated with Baf.
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secretion. Double knockdown of Gorasp1 and Gorasp2 inhib-
ited IDE secretion from astrocytes (Fig. 5E). To determine if
any particular GORASP is required for IDE secretion, siRNA
for Gorasp1 or Gorasp2 was transfected into astrocytes. Both
GORASP1 and GORASP2 reduced Ab-induced IDE secretion,
indicating that both are important for IDE secretion (Fig. S6A
and B). To examine how the GORASP protein regulates IDE
secretion, involvement of autophagy was examined because
previous studies reported that GORASP2 controls autophagy
initiation in macrophages.13 When the effect of knockdown of
Gorasp1 and Gorasp2 in astrocytes was examined, the LC3-II
level was reduced, and the SQSTM1 (sequestosome 1) level
increased in the Gorasp1, 2 double-knockdown astrocytes
(Fig. 5F). In addition, when the Tf-LC3 construct was trans-
fected to scrambled siRNA- or Gorasp1, 2 siRNA-transfected
cells, Gorasp1, 2 double-knockdown cells showed decreased
mRFP and yellow dot numbers with Ab and/or Baf treatments
(Fig. S6C and D). When the autophagy inducers such as rapa-
mycin were applied to Gorasp1, 2 double-knockdown cells, we
found that Gorasp1, 2 double-knockdown cells showed
decreased LC3-II levels compared to scrambled siRNA-trans-
fected cells (Fig. S6E). These data indicate that GORASP regu-
lates IDE secretion by modulating autophagy.
Autophagy-insufﬁcient mouse brains show decreased IDE
levels in the CSF, with Ab-injection
The above in vitro data showed increased IDE secretion from
Ab-treated astrocytes, mediated by an autophagy-based uncon-
ventional secretory pathway. Consistent with the in vitro data,
we examined whether Ab-induced IDE secretion occurs via the
autophagy-based secretory pathway in vivo using mice with
Figure 4. The SlyX domain of IDE regulates IDE degradation through lysosomes. (A) Protein stability in IDE wild-type (IDE WT) and SlyX domain-deletion mutant (IDE DS)-
transfected U373MG cells after cycloheximide (CHX) treatment. , P < 0.01 vs. IDE protein levels immediately (0 h) after CHX treatment. (B) The increased degradation of
IDE DS through lysosomes in the Ab treatment (1 mM for 24 h). Baf (10 nM for 2 h). (C) Quantitative analysis of Fig. 4B (N D 3 experiments). , P < 0.01 vs. vehicle-
treated, IDE DS-GFP-transfected cells; ##, P < 0.01 vs. IDE DS-GFP-transfected cells treated with Ab. (D) The reduced secretion of IDE DS compared to IDE WT protein. (E)
Quantitative analysis of Fig. 4D (N D 3 experiments). , P < 0.05; and , P < 0.01 vs. vehicle-treated cells; #, P < 0.05; and ##, P < 0.01 vs. cells treated with Ab; &, P <
0.05 vs. IDE WT-GFP-transfected cells, treated with Ab.
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global haploinsufﬁciency of an essential autophagy gene (Atg7C/
¡ mice). The brains from Atg7C/¡ mice showed reduced Atg7
mRNA and protein levels (Fig. 6A and B), decreased LC3-II lev-
els, and increased SQSTM1 levels, a substrates for autophagic
protein degradation, as previously reported (Fig. 6B and C).32
With the i.c.v. injection of Ab into the 2- to 3-mo-old- Atg7C/C
and Atg7C/¡ mice for 2 wk, increased autophagy (represented by
an increase in LC3-II levels) in the brains of Atg7C/C mice, but
not Atg7C/¡ mice were detected (Fig. 6B and C). IDE levels (and
activity) were detected in the CSF because CSF has more physical
Figure 5. Ab-induced IDE secretion is mediated by RAB8A activity and GORASP. (A) WB analysis of secreted IDE levels in the media from Rab5 or Rab8a knockdown pri-
mary astrocytes under treatment with Ab or vehicle. Representative images are shown, and data are represented as mean § SEM from 3 independent experiments (N D
3 experiments). (B) Association of Ab-induced IDE secretion with RAB8A activity in primary astrocytes. RAB8A DN indicates a dominant-negative mutant form of RAB8A
(RAB8AS22N) (N D 3). (C) Effect of prenylated proteins on Ab-induced IDE secretion (1 mM for 24 h). (D) Effect of RAB8A on Ab-induced IDE secretion, with a RAB8A preny-
lation-deﬁcient mutant. Ab (1 mM) treatment was applied to RAB8A WT or RAB8AC204A-transfected astrocytes for 24 h (N D 3). (E) WB analysis of IDE secretion from Atg5
knockdown and Gorasp (Gorasp1 and Gorasp2) double-knockdown astrocytes. Ab (1 mM for 24 h); Baf (10 nM for 2 h) (N D 4). (F) Inhibition of autophagy in Gorasp1,2
double-knockdown astrocytes (N D 3). GOLGA2 was used as a marker for Golgi apparatus. , P < 0.05; and , P < 0.01 vs. vehicle-treated cells; #, P < 0.05; ##, P < 0.01;
and ###, P < 0.001 vs. cells treated with Ab.
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contact with the brain than any other ﬂuid. By ELISA and enzy-
matic activity assay for IDE in the CSF, Ab-injected Atg7C/¡
mice showed a signiﬁcant reduction in the IDE level and activity
as compared to Atg7C/Cmice (Fig. 6D and E). These data suggest
that Ab-induced IDE secretion is mediated by autophagy in vivo.
IDE activity is inversely correlated with age in AD mice
Previous studies have demonstrated accumulated autophagy in
AD brains, and suggested that dysregulated autophagy regulates
the progression of AD.17,33 Because IDE secretion is associated
with Ab-induced autophagy from the aforementioned data, the
regulation of IDE secretion in Tg6799 mice, an AD mouse
model,20 was examined. Since the Tg6799 mice are known to
overexpress Ab, have amyloid plaque deposition in the subicu-
lum at 2 mo of age, and exhibit reduced synaptic markers, neu-
ronal loss, and memory impairment at 6 mo of age,20 1.5-mo-
old (before plaque formation) and 7-mo-old (after plaque for-
mation) Tg6799 mice were used in this study. Both 1.5-mo-old
(young) and 7-mo-old (old) Tg6799 mice showed increased Ab
and autophagy levels (Fig. 7A), but only the old Tg6799 mice
showed defects in the lysosomes (decreased ATP6V0A1 and
CTSD mature form) (Fig. 7A). Electron microscopy analysis
showed increased AVs in the old Tg6799 mice (Fig. S7A). To
examine the secreted IDE levels, ELISA and enzymatic activity
assays for the IDE protein were performed on the CSF from
the Tg6799 mice and littermate control mice. IDE activity and
protein levels increased in the CSF of the young Tg6799 mice,
however, the old Tg6799 mice showed decreased IDE activity
and levels in the CSF (Fig. 7B and C). Based on Figure 3 in this
study, IDE secretion is increased when the lysosomal function
is intact to form autolysosomes in the young Tg6799 mice
(Fig. 7A). As the lysosomal function is defective in the old
Tg6799 mice (Fig. 7A), autophagic ﬂux is inhibited, and Ab-
induced IDE secretion is reduced, followed by accumulation of
Ab and AVs in the brain (Fig. S7A).
Decreased enzymatic activity of IDE in the CSF of patients
with AD
Since previous reports show accumulated autophagosomes and
dysfunction in lysosomes in the AD-afﬂicted brain,33,34 IDE
Figure 6. Autophagy-insufﬁcient mouse brains show decreased IDE levels in the CSF under Ab-injection conditions. (A) The analysis of Atg7 mRNA level by qPCR in the
cortex and hippocampus of vehicle-injected Atg7C/C and Atg7C/¡ mice (2- to 3-mo-old, N D 6 each group). , P < 0.01; , P < 0.001 vs. vehicle-injected Atg7C/C mice.
(B) WB analysis of LC3, SQSTM1, or ATG7 expression in vehicle or Ab-injected Atg7C/C and Atg7C/¡ mice. DDIT3 was used to measure the level of ER stress. (C) Quantita-
tive analysis of Fig. 6B. (D) IDE enzymatic activities in the CSF of vehicle or Ab-injected Atg7C/C and Atg7C/¡ mice. (E) Results of quantiﬁcation of IDE levels detected with
ELISA in the CSF of vehicle or Ab-injected Atg7C/C and Atg7C/¡ mice. (N D 6 each group) , P < 0.05; , P < 0.01; , P < 0.001 vs. vehicle-injected Atg7C/C mice; #,
P < 0.05; ##, P < 0.01 vs. Ab-injected Atg7C/C mice; x, P < 0.05 vs. vehicle-injected Atg7C/¡ mice. n.s. indicates not signiﬁcant.
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activity and levels in the CSF of patients with AD were mea-
sured. When the IDE activity and levels in the CSF from AD
patients (Table S1A and B) were measured, both activity and
levels of IDE decreased in the CSF of AD patients (Fig. 8A and
E). These results showed a signiﬁcant positive correlation with
MMSE scores (Fig. 8B and F), and, although not signiﬁcant, a
negative correlation tendency with CDR in the AD groups
(Fig. 8C and G). There was no difference between genders
(Fig. 8D and H). These results indicate that AD patients have
reduced IDE protein levels and decreased enzymatic activity of
the same, in their CSF, and that these correlate with cognitive
impairment.
Discussion
In this study, we found that IDE secretion from astrocytes
under conditions of AD pathology is regulated by autophagy
(Fig. 8I). IDE is well known as a major protease for
Ab degradation, and the regulation of functional IDE secre-
tion is important in AD progression. Prior to our work, it was
known that, as IDE has no signal sequences, it is secreted
from the microglia via an exosome-associated unconventional
secretory pathway under statin treatment.35 To determine
whether Ab-induced IDE secretion is associated with exo-
somes in astrocytes, both exosomes and nonexosome fractions
were isolated from vehicle- or Ab-treated ACM. Ab increased
the IDE secretion both in the exosomes and nonexosome frac-
tions (Fig. S8A and B), indicating that the secretory pathway
for IDE is mediated by both exosome- and nonexosome- asso-
ciated pathways. Next, to determine whether Ab-induced IDE
secretion is caused by cell death, cell death assays were per-
formed. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) and calcein-AM assays were performed
(Fig. S9A and B). We found that treatment with 1 or 2 mM of
Ab for 24 h did not induce cell death in astrocytes. The mito-
chondrial uncoupling agent, CCCP, induced cell death as indi-
cated by a positive control cell death assay. To conﬁrm this
result, TdT-mediated dUTP nick-end labeling (TUNEL) assay
was performed (Fig. S9C). Consistent with the results of MTT
and calcein-AM assay, Ab did not induce cell death in this
study. These results indicate that Ab-induced IDE secretion is
not caused by cell death. We examined the mechanisms
underlying IDE secretion, especially under AD conditions,
and found that Ab increased functional IDE secretion in a
time- and dose-dependent manner, and that this Ab-induced
IDE secretion was blocked by autophagy inhibition. Because a
fundamental role of autophagy is the clearance of protein
aggregates and pathogens, we investigated whether IDE secre-
tion is regulated by the autophagy-lysosome pathway. When
lysosomes were disrupted by the lysosomal inhibitor Baf, IDE
Figure 7. IDE activity is inversely correlated with age in AD mice. (A) Lysosomal dysfunction in the brain of the 7-mo-old Tg6799 mice (old Tg), and in 1.5-mo-old Tg6799
(young Tg) mice. LT, age matched littermate controls; Tg, Tg6799; CTSD, cathepsin D. CANX is a loading control for the membrane fraction of the brain tissue, and GAPDH
is a loading control for the total lysates. (B) IDE enzymatic activities in the CSF of 1.5-mo-old and 7-mo-old Tg6799 mice (and littermate controls). (C) Results of quantiﬁca-
tion of IDE levels detected with ELISA in the CSF of LT and Tg mice. Values are mean§ SEM , P< 0.05; and , P< 0.01 vs. young LT; #, P< 0.05; and ##, P< 0.01 vs. old
LT. RFU, relative ﬂuorescence unit.
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secretion was blocked, and inversely, cotreatment with a lyso-
some activator, PP242, restored IDE secretion. These data
indicate that autophagic ﬂux is important for IDE secretion.
From our in vivo data using AD-model mice, we found that
the IDE activity and levels increased in the CSF of the young
(1.5-mo-old) Tg6799 mice, while the old (7-mo-old) Tg6799
mice showed decreased IDE activity and protein levels in the
CSF. These were consistent with the in vitro data because the
old Tg6799 mice brains showed lysosomal dysfunction
(decreased ATP6V0A1 and matured form of CTSD levels or
increased AVs shown in EM images based on previous stud-
ies) (Fig. 7; Fig. S7).36 In addition, patients with AD showed
decreased IDE activity and levels in the CSF, and this reduc-
tion is correlated with cognitive impairment (Fig. 8). These
data suggest that because the defect in the lysosome is a causa-
tive risk factor for AD, modulation of the lysosomal activity
may serve as a novel therapeutic target in AD treatment by
regulating IDE secretion.
It is surprising that IDE can be secreted from astrocytes via
the autophagy-lysosome pathway. How can IDE proteins escape
the acidic and harsh environment of the lysosome without degra-
dation? The lysosomal lumen contains approximately 60 differ-
ent soluble hydrolases, which are active in the acidic
environment of the lumen (pH 4.5–5.0).37 Many lysosomal pro-
teins, such as lysosomal-associated membrane protein 1
(LAMP1) and cathepsins, are protected from lysosomal degrada-
tion by post-translational modiﬁcations such as mannose-6-
phosphate tagging or hyper-glycosylation. Since IDE does not
have these modiﬁcation sites, we investigated mechanisms other
than lysosomal degradation. We found that the SlyX domain
(EKPPHY) of IDE contributes to the Ab-induced IDE secretion
by preventing its lysosomal degradation (Fig. 4), although the
Figure 8. Decreased enzymatic activity and protein levels of IDE in the CSF of patients with AD. (A) IDE enzymatic activities in the CSF of control subjects and patients with
AD (N D 10 in each group). RFU, relative ﬂuorescence unit. (B) IDE activity data from the CSF show a correlation with the MMSE score (r D 0.4657, P value D 0.0385). (C)
IDE activities in the CSF of AD patients show a tendency of negative correlation with AD group CDR scores (r D ¡0.0809, P D 0.4120). (D) Gender difference in IDE enzy-
matic activities. (E) IDE expression levels in the CSF of control subjects and patients with AD (N D 10 in each group). (F) The levels of IDE proteins in the CSF correlate
with the MMSE score (r D 0.5155, P value D 0.0200). (G) Like IDE activity, IDE protein levels in the CSF of AD patients show a negative correlation with CDR scores calcu-
lated in the AD groups (r D ¡0.4042, P D 0.2467). (H) Gender difference in IDE levels in the CSF. Values are mean § SEM , P < 0.05; , P < 0.01. ‘n.s.’ means not signiﬁ-
cant. (I) Schematic diagram of this study. Ab increases IDE secretion from astrocytes via an autophagy-based unconventional secretory pathway, and Ab-induced IDE
secretion depends on the activity of RAB8A and GORASP. In the AD brain, lysosomal dysfunction occurs and, as a result, Ab-induced IDE secretion is inhibited because
autophagic ﬂux is important for IDE secretion. Reduced IDE levels may result in increased levels of extracellular Ab and contribute to the progression of AD pathogenesis.
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mechanism by which it does so is not yet known. Indeed, the
SlyX domain is present in other proteins (HS3ST/heparan sulfate
proteoglycans and PLSCR1 [phospholipid scramblase 1]), and
these proteins are reportedly secreted via the unconventional
secretory pathways.38,39 We will, in a future study, try to identify
the binding partner on the SlyX domain of IDE, and establish
whether such a structure may confer a protective effect to IDE
during lysosomal degradation. In this study, we found that IDE
might be a substrate for the proteasome. Treatment with
MG132, a proteasome inhibitor, increased both intracellular and
extracellular IDE levels, as well as LC3-II levels (Fig. S3A and B).
An association between the proteasome and autophagy has been
noted in previous studies,40 and we further found that MG132
treatment increased LC3-II levels in astrocytes. These results sug-
gest that MG132 treatment increased IDE secretion both by
increasing IDE protein levels and by autophagy induction. In a
future study, we will check whether MG132 regulates key pro-
teins of secretory autophagy (such as RAB8A or GORASP), as
well as total autophagy levels. Results of this study have shown
that application of 1 mM Ab reduces proteasome activity by
approximately 20% (data now shown) and activates autophagy
in astrocytes; thus, IDE may escape degradation by the protea-
some and autophagic secretion from astrocytes treated with Ab.
What are the regulatory factors for the autophagy-based
secretion of IDE? We focused on the RAB proteins because
they play multiple roles in the secretory pathway.26 According
to our data, among the RAB proteins, RAB8A was important
for IDE secretion. Speciﬁcally, IDE secretion was mediated by
RAB8A activity, and Ab increased IDE secretion from astro-
cytes by the inhibition of RAB8A prenylation. Although it is
indirect evidence, previous studies have shown that statin treat-
ment increases IDE secretion, and inhibits protein prenyla-
tion.35,41 Whether IDE secretion by statin treatment occurs
through same pathway as Ab treatment should be investigated.
Further, how IDE inside the lysosome is transported to the
extracellular medium needs to be determined. Previous studies
reported the topological inversion properties of autophagy, fer-
rying molecules from the cytosol to the lumen of secretory
vesicles, however, this wanes quickly with time.42,43 In addition,
the core secretory machinery for vesicle exocytosis consists of
SNAREs (N-ethylmaleimide-sensitive factor attachment pro-
tein receptors) and sec1/STXBP/Munc18-like proteins.44 The
marker protein of secretory lysosomes as the major vesicular
compartment for Ca2C-regulated exocytosis from astrocytes45 is
VAMP7/TI-VAMP (vesicle associated membrane protein 7).46
Verderio et al. (2012)47 report that VAMP7 is the SNARE of
secretory lysosomes contributing to ATP secretion from astro-
cytes. Considering that ATP is a cytosolic protein, which can be
secreted from astrocytes following Ab treatment,48 and that
ATP is known as a protein secreted via an autophagy-based
unconventional secretory pathway,49 VAMP7 might play a role
as a regulatory factor for Ab-induced autophagy-based secre-
tion of IDE. In a future study, we will investigate the effect of
possible regulatory factors on IDE secretion from astrocytes.
Astrocytes play a critical role in maintaining neuronal
homeostasis by providing energy, eliminating waste, and regu-
lating ionic ﬂux.50 Furthermore, astrocytes are well-positioned
both metabolically and anatomically to play an important
homeostatic role under basal conditions, as well as in
pathological conditions such as AD. Astrocytes are activated to
degrade Ab at an early stage of AD. For the removal of extracel-
lular Ab, astrocytes take up Ab bound to membrane receptors
via endocytosis,51 and degrade Ab in the lysosomes. In a recent
study, enhancing astrocytic lysosome biogenesis facilitates Ab
clearance, and attenuates AD pathogenesis.52 Our results sug-
gest another mechanism for the blockade of Ab toxicity by
astrocytes. In other words, we found that Ab could be degraded
by inducing IDE secretion from astrocytes via autophagy-based
secretory pathway under AD conditions. In previous studies,
IDE is expressed in several cell types in brain such as neurons
and endothelial cells as well as astrocytes,53,54 however,
Dorfman et al.4 show that astrocytes are the main cell types for
IDE in AD pathology. In addition, when neurons, astrocytes or
endothelial cells were treated with Ab, we found that only
astrocytes increased IDE secretion (Fig. S10). For detection of
secreted IDE in vivo, we used the CSF of humans and mice as
previously described.55 CSF is a translucent body ﬂuid that
occupies the subarachnoid space and the ventricular system
around the brain.56 CSF protects the brain by providing
mechanical and immunological defense. CSF can be obtained
via a lumbar puncture, and is probably the most informative
biomarker for the prognosis of neurodegenerative diseases. As
a result, proteins or peptides that may be directly reﬂective of
brain-speciﬁc activities, as well as of disease pathology, would
most likely diffuse into the CSF, rather than into any other
bodily ﬂuid. These proteins and metabolites can serve as excel-
lent biomarkers of AD as well as other neurodegenerative
diseases.56
The regulation of Ab levels is of great interest for its thera-
peutic potential in AD. Apart from the interference with Ab
generation, a promising alternative may be the enhancement of
Ab degradation by targeting Ab-degrading enzymes.57 Many
reports highlight the impact of decreased Ab clearance from
the central nervous system in late-onset AD.58 Thus, regulating
autophagy-based secretion of IDE by modulating lysosomal
activity in astrocytes may lead to new therapeutic approaches
for sporadic AD.
Materials and methods
Study participants
The subject population for this study included patients from
the Soonchunhyang University Bucheon Hospital, South Korea,
with a diagnosis of probable AD along with healthy controls.
Participants were diagnosed by National Institute of Neurologi-
cal and Communicative Disorders and Stroke–Alzheimer Dis-
ease and Related Disorders Association criteria and CDR of 0.5
(mild AD) – 3.0 (severe AD). Clinical evaluation included med-
ical history, physical examination, MMSE, and CDR. All those
with available biochemical measures were included in the
study, resulting in 10 subjects with AD and 10 healthy controls
(IRB No. SCHBC_IRB_2012-124) (Table S1A and B).
CSF preparation
For preparation of the CSF samples from AD and control sub-
jects, CSF was obtained through lumbar punctures, which were
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performed between 8 and 10 a.m. subsequent to an overnight
fast. After collection of 5 mL in a polypropylene tube, the CSF
was centrifuged, and aliquoted into 1.0-mL polypropylene
tubes. The tubes were stored at -80C until analysis was per-
formed. Isolation of the CSF from mice was performed as
described previously.59
Animals
The Tg6799 mice (formerly JAX Stock No. 008730) overexpress
the mutant human APP (amyloid b precursor protein) form
with the Swedish (K670N, M671L), Florida (I716V), and
London (V717I) familial AD (FAD) mutations, and human
PS1 harboring 2 FAD mutations, M146L and L286V.20 Non-
transgenic littermate controls (B6SJL) were used for the experi-
ments. All mice were purchased from Jackson Laboratories
(Bar Harbor, ME, USA), and the animals were treated and
maintained in the Seoul National University’s mouse facility.
Atg7C/¡ and Atg7C/C mice (N D 12 each group) were kindly
provided by Dr. Myung-Shik Lee (Sungkyunkwan University
School of Medicine, Korea).32 Ab or phosphate-buffered saline
(PBS) was administered via i.c.v. injections into 2- to 3-mo-
old-Atg7C/¡ and Atg7C/C mice as previously described with
some modiﬁcation.60 Brieﬂy, the mice received a single i.c.v.
injection into the lateral ventricles using a Hamilton syringe
(Fisher Scientiﬁc Co, Pittsburgh, Pennsylvania, USA) 2 weeks
before the experiments were performed, while being secured in
a stereotactic apparatus (Harvard Apparatus, Holliston, MA).
The coordinates according to bregma were ¡0.9 mm
lateral, ¡0.1 mm posterior, and ¡3.1 mm below. All experi-
ments involving animals were performed according to proto-
cols approved by the Seoul National University Institutional
Animal Care and Use Committee (SNU IACUC) guidelines.
Cell cultures, drug treatments, and transfection
The human astroglioma U373MG cells (ATCC, HTB-17),
human neuroblastoma SH-SY5Y cells (ATCC, CRL-2266) and
mouse brain endothelial cell line BEND3 (ATCC, CRL-2299)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Sigma-Aldrich, D6546) containing 10% fetal bovine serum
(FBS), 0.1 mg/mL penicillin/streptomycin and 2 mM L-gluta-
mine (Sigma-Aldrich, G7513) at 37C under humidiﬁed 5%
CO2 air. The U373MG cells (5 £ 105 cells) were plated onto 6-
well plates. Primary neurons were prepared from E18 ICR
mouse embryos, and primary astrocytes were prepared from
newborn (P1) ICR mice as described previously.48 Astrocytes
underwent 2 passages for the experiments. Cells were treated
with several reagents alone, or cotreated with Ab followed by a
24 h incubation. The reagents used in this study were the fol-
lowing: thiorphan (T6031), bacitracin A (B0125), insulin
(I2643), 3MA (M9281), MG132 (M7449), GGPP (G6025),
PP242 (P0037), baﬁlomycin A1/Baf (B1793), chloroquine
(C6628) from Sigma-Aldrich; and rapamycin (LC Laboratories,
R-5000). The cDNAs in this study were purchased from Ori-
gene (IDE-GFP; RG220700) or Addgene (24898 for Rab8a;
24899 for Rab8aS22N) and the siRNAs were purchased from
Bioneer Inc. (Daejeon, Korea). cDNA and siRNA were trans-
fected into the cells using Lipofectamine 2000 (11668027) and
RNAimax (13778) from Invitrogen according to the manufac-
turer’s instructions or by electroporation (ECM 830 Square
Wave Electroporation System, Harvard Apparatus).
Western blot analysis
Harvested cell pellets and mouse brain lysates were prepared
as described elsewhere.61 The antibodies for the western blot
analysis were: anti-LC3B antibody (1:2,000; MBL, M152-3;
and Cell Signaling Technology, 2775); anti-Beta-amyloid (Ab)
1-16 (6E10) antibody (1:5000; Biolegend, 803016); anti-
RAB8A (6975), anti-ATG5 (12994), anti-ATG7 (8558), anti-
CANX (calnexin) (2433), anti-p-PRKAA1/2 (T172) (2535),
anti-PRKAA1/2 (2532), anti-p-RPS6KB (T389) (9205) and
anti-RPS6KB (2708) (1:2000, Cell Signaling Technology); anti-
DDIT3 (DNA damage-inducible transcript 3) (sc-575), anti-
MMP9 (sc-6840), anti-GORASP2 (sc-271840), anti-GORASP1
(sc-19481), anti-ATP6V0A1 (sc-28801), anti-CTSD (sc-6486),
anti-RAB5A (sc-309) and anti-GFP antibody (sc-9996)
(1:1,000; Santa Cruz Biotechnologies Inc.); anti-IDE
(ab32216), anti-GAPDH (ab9485), anti-TSG101 (ab83), anti-
LAMP1 (ab25245), and anti-HMGB1 antibody (ab18256)
(1:2,000; Abcam); anti-GOLGA2 (golgin A2) (1:4,000; BD Bio-
Science, 610822); anti-SQSTM1 (P0067), and anti-ACTB
(actin, beta) (A1978) (1:4,000; Sigma-Aldrich). Immunoreac-
tivity was determined by chemiluminescence (GE Healthcare,
RPN2108). The chemiluminescence signal was detected with a
digital image analyzer (LAS-3000; Fuji, Tokyo, Japan).
Preparation and quantiﬁcation of Ab
Ab was prepared as previously described.17 Most of the Ab
used exists as oligomers and some monomers. For quantiﬁca-
tion of Ab, sandwich enzyme-linked immunosorbent assay
(ELISA) was performed as described for Ab quantiﬁcation.61
Ab degradation assays
Ab degradation assays were performed as previously described,
with some modiﬁcation.35 Brieﬂy, primary astrocytes or
U373MG cells grown in a 6-well plate to 70% conﬂuency were
incubated with Ab42 or DMSO (vehicle) for 24 h. After PBS
(Sigma-Aldrich, P4417) washing, cells were incubated for an
additional 6 h in serum-free OPTI-MEM (GIBCO, 31985-070).
The supernatant fraction (vehicle- or Ab-ACM) was then col-
lected after centrifugation and incubated with 1 mM Ab for
12 h at 37C in the absence or presence of 10 mg/mL bacitracin
A, 0.3 ng/mL recombinant IDE (rIDE) (R&D Systems, 31985-
070), or 0.5 mM insulin. The remaining Ab levels were quanti-
ﬁed by western blot analysis with 6E10 antibody, which can
detect both Ab40 and Ab42 peptides.
Trichloroacetic acid (TCA) precipitation
For analyzing protein in the medium, we performed TCA pre-
cipitation as previously described.61 Brieﬂy, cell medium was
centrifuged at 5,000 rpm for 5 min to remove cell debris and
subjected to TCA precipitation (up to 10%) (Sigma-Aldrich,
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T6399). By TCA precipitation with media, 40X concentrated
samples were loaded on the SDS-PAGE gels.
IDE enzymatic activity assay and IDE level measurement
The IDE enzymatic activity in the CSF or media was deter-
mined per the manufacturer’s protocol (Calbiochem, CBA079).
Brieﬂy, 5 mL of the CSF from mouse and 50 mL of the CSF
from human were diluted with PBS, and loaded into in a 96-
well plate, which contained an afﬁnity-puriﬁed polyclonal anti-
body that recognizes IDE (Calbiochem, CBA079). Following
1-h incubation, substrate was added and incubated for 2 to 4 h
at 37C in the dark. The ﬂuorescence was measured using an
excitation wavelength of 320 nm and an emission wavelength
of 405 nm. The relative ﬂuorescence unit represents total IDE
activity in the media or CSF without normalizing to IDE pro-
tein levels. Cell media were concentrated with Amicon Ultra ﬁl-
ter (UFC510024, Millipore, Billerica, MA). To determine the
protein level of IDE in the media and CSF, ELISA was per-
formed according to the manufacturer’s protocol (Mybio-
source, MBS018913 and MBS725082).
Partial puriﬁcation of lysosomes
Partial isolation of lysosomes was performed as previously
described.62 Brieﬂy, cells were resuspended in a hypotonic
buffer (10 mM KCl, 30 mM Tris, pH 7.5, 5 mM MgOAc, 1 mM
b-mercaptoethanol) and dissociated by piston strokes. Homo-
genates were centrifuged at 1,000 X g to precipitate the nuclei,
then the supernatant fractions were collected and centrifuged
at 100,000 X g for 1 h at 4C.
Measurement of lysosomal activity
The lysosomal activity was determined as per the manufac-
turer’s protocol (pepstatin A-BODIPY-conjugate [Molecular
Probes, P12271] and LysoTracker Red [Molecular Probes,
L7528]).
Isolation and characterization of exosomes
Exosomes and nonexosome fractions in the media from astro-
cytes were prepared as described earlier.63
Cell viability assay
To measure cell viability, we performed MTT, calcein-AM and
TUNEL assays (Promega, G7130) as previously described.64 To
analyze the TUNEL assay results, similar cell numbers from
each group were analyzed (n D 300). Data are represented as
the mean § SEM from 3 independent experiments (N D 3).
Separation of prenylated and unprenylated RAB protein
RAB protein prenylation was examined by extraction of preny-
lated proteins with Triton X-114 (Sigma-Aldrich, X114) as pre-
viously described.29
Examination of LC3-II translocation
To analyze green ﬂuorescent protein (GFP)-LC3, red ﬂuores-
cent protein (RFP)-LC3, and tandem-ﬂuorescence LC3
(Tf-LC3), plasmids encoding GFP-LC3, RFP-LC3, and Tf-LC3
(a gift of Dr. Lee, Sungkyunkwan University, Korea) were
transfected into astrocytes. The appearance of RFP-LC3 and
GFP-LC3 puncta was visualized on a confocal laser-scanning
microscope (FV10i-w; Olympus, Tokyo, Japan).
RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from astrocytes treated with vehicle
or Ab using TRIzol reagent (Life Technologies, 15596-026).
The following sense and antisense primers were used for mouse
Ide: 5- TCTCCTTCCAAGTCAGCTGGT -3 (sense), 5- TTGG
AAGGCCTCTTCTGTCAT -3 (antisense).
Quantitative real-time PCR (qPCR)
To examine the levels of mouse IdemRNA, qPCR was performed
as previously described.64 The following sense and antisense pri-
mers were used: 50-TACCTCCGCTTGCTGATGACTG-30
(sense), 50-ACAGGAGCTGAGGTATGAAGGC-30 (antisense)
for Ide; 50-ACAGCCGCATCTTCTTGTGCAGTG-30(sense), 50-
GGCCTTGACTGTGCCGTTGAATTT -30 (antisense) forGapdh.
3D-SIM (super resolution structured illumination
microscopy)
To check the colocalization of IDE and autophagosomes, we
used the super-resolution structured illumination microscopy
(SIM; Nikon N-SIM). 3D-SIM images were taken for each ﬁxed
cell by moving the stage in the z-direction with a step size of
0.150 mm. The sequential z-sections were reconstructed to a
3D-SIM image (z-axis; brain slice thickness »5.0 § 0.4 mm)
and the 3D-deconvolution with the a blending function using
NIS-E software (Nikon, Tokyo, Japan) was created. Images
were taken by an Eclipse Ti-E research inverted microscope
(Nikon, Tokyo, Japan) with Nikon’s CFI Apo TIRF 100£ oil
objective lens (NA 1.49) and iXon DU-897 EMCCD camera
(Andor Technology, Tokyo, Japan) at 512 £ 512 pixel resolu-
tion. Multicolor ﬂuorescence was acquired using a diode laser
(488 nm, 561 nm) and exposure times of 40 ms, electron micro-
scopic (EM) gain of 150, conversion gain of 1£ were applied.
The image was processed with NIS-E software and later
exported to the Adobe Photoshop program.
Immunostaining
Immunocytochemical staining was performed as described pre-
viously.21 Brieﬂy, the ﬁxed cells were incubated with mouse
anti-IDE (1:300) or anti-LC3B (1:300) or anti-RAB8A (1:300)
primary antibodies in PBST (PBS with 0.2% Triton X-100
[Sigma-Aldrich, T8787]) buffer overnight at 4C. After several
washes, the cells were incubated with secondary antibody, and
images were taken on a confocal laser scanning microscope
(FV10i-w).
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Electron microscopy (EM)
Brain tissues of Tg6799 mice and the littermate control mice
were ﬁxed overnight in a mixture of cold 2.5% glutaraldehyde
in 0.1 M phosphate buffer (pH 7.2) and 2% paraformaldehyde
in 0.1 M phosphate or cacodylate buffer (pH 7.2) and embed-
ded with epoxy resin. The epoxy resin-mixed samples were
loaded into capsules and polymerized at 38C for 12 h and
60C for 48 h. Thin sections were sliced on an ultramicrotome
(RMC MT-XL; RMC Products, Tucson, AZ, USA) and col-
lected on a copper grid. Appropriate areas for thin sectioning
were cut at 65 nm and stained with saturated 4% uranyl acetate
and 4% lead citrate before examination on a transmission elec-
tron microscope (JEM-1400; JEOL, Tokyo, Japan) at 80 kV.
Data analysis and statistics
For western blots, protein levels were normalized to pan forms
or a housekeeping protein, such as ACTB or GAPDH. All data
were expressed as means § standard error of the mean (SEM).
Statistical analysis was performed using GraphPad Prism5 (San
Diego, CA, USA). The Student t test was used for 2-group com-
parisons, and one-way analysis of variance (ANOVA) followed
by the Tukey-Kramer multiple comparison test was used to
compare 3 or more groups. P values of < 0.05 were considered
statistically signiﬁcant.
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3-MA 3-methyladenine
AD Alzheimer disease
Ab amyloid beta
AMPK AMP-activated protein kinase
APP amyloid beta precursor protein
ATG autophagy related
AVs autophagic vacuoles
ATP6V0A1 ATPase, HC transporting, lysosomal V0 sub-
unit a1
ACM astrocyte-conditioned media
ACTB actin, beta
BBB blood brain barrier
BFA brefeldin A
Baf baﬁlomycin A1
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CHX cycloheximide
CTSD cathepsin D
DDIT3 DNA damage inducible transcript 3
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ELISA enzyme-linked immunosorbent assay
EM electron microscopy
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GORASP Golgi reassembly stacking protein
GGPP geranylgeranylpyrophosphate
GORASP KD GORASP1 and GORASP2 double-knockdown
cell
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
GOLGA2 golgin A2
HMGB1 high mobility group box 1
IDE insulin-degrading enzyme
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IL1B interleukin 1, beta
IL18 interleukin 18
LC3A/B microtubule associated protein 1 light chain 3
alpha/beta
LRP1 LDL receptor related protein 1
MTOR mechanistic target of rapamycin (serine/threo-
nine kinase)
MMSE mini-mental state examination
MMP9 matrix metalloproteinase 9
MDC monodansylcadaverine
PBS phosphate-buffered saline
RPS6KB ribosomal protein S6 kinase 70kDa
RT-PCR reverse transcription polymerase chain reaction
qPCR quantitative real-time PCR
SIM super-resolution structured illumination
microscopy
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
Tf-LC3 monomeric RFP (mRFP)-GFP tandem ﬂuores-
cence tagged LC3
TCA trichloroacetic acid
TSG101 tumor susceptibility 101
VWF von Willebrand factor
WB western blotting
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